Chronic kidney disease is a multifactorial illness with a steadily increasing global prevalence. It has been established that this disease primarily affects older patients. Aging brings a series of structural and functional changes, leading to altered pharmacokinetics and pharmacod ynamics of drugs in the elderly. Such patients often suffer from multiple comorbidities, resulting in the prescription of numerous medications and the issue of polypharmacy and polypragmasy. Many prescribed drugs can be potentially inappropriate or risky considering the reduced renal function in patients with chronic kidney disease (CKD). The aim of this research was to analyze the pharmacotherapy of the study participants, all older than 6 5 years and suffering from CKD, using the best possible medication history (BPMH) and to identify potentially inappropriate medications (PIMs) using the EU(7)-PIM guidelines and risky medications in relation to the degree of renal impairment. Identifying PIMs and risky drugs will allow for deprescription opportunities in such patients. The study involved 26 patients admitted and hospitalized at KB Dubrava in Zagreb. Data for all patients was collected using the BPMH form within 24 hours of patient's admission to KB Dubrava. Analyzing the collected data from the form, polypha rmacy was identified for each participant. PIMs were identified using the EU(7)-PIM list guidelines, while risky drugs were identified according to HALMED recommendations. According to the study results, polypharmacy was found in 92.3 % of the participants, with 58.3 % of patient s taking 5-9 drugs in their therapy, and 38.5 % taking 10 or more drugs. The most common drugs were from the ATC group C, which act on the heart and blood vess els. A total of 54 PIMs were identified, and 84.6 % of patients had at least one PIM in their therapy. The most common PIMs were pa ntoprazole, moxonidine, and tramadol. Furthermore, data analysis revealed 20 drugs that required dose adjustment, while a total of 23 drugs present i n the therapies of the participants were contraindicated considering the degree of renal impairment. The obtained results clearly indicate that deprescription is of particular importance for patients with CKD. It is crucial to evaluate the possibility of deprescription at admission, during hospitalization, and at discharge. In this process, the clinical pharmacist should play an important role in coordination with other healthcare professionals and the patient themselves.